Suspension of trading

TFF Pharmaceuticals, Inc. Stock Nasdaq

Stocks

TFFP

US87241J2033

Biotechnology & Medical Research

Delayed 16:00:00 2024-12-12 EST 5-day change 1st Jan Change
0.0650 USD -60.05% Intraday chart for TFF Pharmaceuticals, Inc. -.--% -

Valuation: TFF Pharmaceuticals, Inc.

Market Cap 10.52M 9.34M 8.74M 7.92M 14.96M 1.01B 15.07M 105M 40.82M 517M 39.48M 38.64M 1.66B P/E 2022 *
-
P/E 2023 -0.61x
Enterprise Value 5.16M 4.58M 4.28M 3.88M 7.33M 497M 7.38M 51.44M 20.01M 254M 19.35M 18.94M 815M EV / Sales 2022 *
-
EV / Sales 2023 15,920,656x
Free-Float
97.4%
Yield 2022 *
-
Yield 2023 -
3 years 0.06
Extreme 0.0611
11
5 years 0.06
Extreme 0.0611
249
10 years 0.06
Extreme 0.0611
528.5
Manager TitleAgeSince
Chief Executive Officer 65 2024-11-13
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - -
Director TitleAgeSince
Director/Board Member 65 2024-11-13
Change 5-day change 1-year change 3-year change Capi.($)
-60.05%-.--% - - 10.86M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.60%+22.80%+78.53% 56.95B
+0.24%-1.34%+3.41%+34.31% 48.3B
-4.50%-3.15%+325.18%+690.93% 44.51B
-1.17%-2.11%+28.43%+32.56% 43.8B
+1.06%-0.30%+5.70%+109.44% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.39%-2.36%-8.48%-13.46% 24.53B
Average -5.49%-0.20%+52.54%+124.46% 43.73B
Weighted average by Cap. +0.88%-0.50%+56.52%+132.93%

Financials

2022 2023
Net sales 0.5 0.44 0.41 0.37 0.71 47.79 0.71 4.95 1.92 24.38 1.86 1.82 78.38 0.73 0.65 0.61 0.55 1.04 70.74 1.05 7.32 2.85 36.09 2.75 2.7 116.02
Net income -31.77M -28.2M -26.39M -23.92M -45.18M -3.06B -45.5M -317M -123M -1.56B -119M -117M -5.02B -21.24M -18.86M -17.65M -16M -30.21M -2.05B -30.43M -212M -82.44M -1.04B -79.74M -78.03M -3.36B
Net Debt -16.42M -14.58M -13.64M -12.36M -23.35M -1.58B -23.52M -164M -63.73M -808M -61.64M -60.32M -2.6B -5.36M -4.76M -4.46M -4.04M -7.63M -517M -7.68M -53.51M -20.81M -264M -20.13M -19.7M -848M
Projected Income Statement - Annual - TFF Pharmaceuticals, Inc.
Logo TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicine into potent dry powder. It is focused on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform. Its TFF technology platform has an applicability to convert any drug, including vaccines, small and large molecules, and biologics, into a dry powder for inhalation, or for topical delivery to the eyes, nose and the skin. TFF Pharmaceuticals has two lead drug candidates in the clinic: TFF TAC (Tacrolimus Inhalation Powder) and TFF VORI (Voriconazole Inhalation Powder). TFF TAC is an inhaled dry powder formulation of tacrolimus, for the prophylaxis of organ rejection in patients receiving lung transplants, in combination with other immunosuppressants. TFF VORI is an inhaled dry powder formulation of voriconazole, for the treatment and prophylaxis of invasive pulmonary aspergillosis.
Employees
19

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - TFF Pharmaceuticals, Inc.